Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359–371 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ali, A. & DiPersio, J. F. ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights. Front. Immunol. 15, 1432799 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21, 501–521 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Rejeski, K., Hill, J. A., Dahiya, S. & Jain, M. D. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat. Med. 31, 2132–2146 (2025).

Article  PubMed  Google Scholar 

Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307–312 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah, N. N. et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 3, 2317–2322 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Sasu, B. J. et al. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. Mol. Ther. 31, 676–685 (2023).

Article  CAS  PubMed  Google Scholar 

Nobles, C. L. et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J. Clin. Invest. 130, 673–685 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ozdemirli, M. et al. Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy. N. Engl. J. Med. 390, 2074–2082 (2024).

Article  CAS  PubMed  Google Scholar 

Perica, K. et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N. Engl. J. Med. 392, 577–583 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hosoya, H. et al. Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine. Blood 147, 1191–1198 (2025).

Article  Google Scholar 

Bezerra, E. et al. Isolated oral CD30+/CD4+ CAR+ T cell lymphoma in long-term remission after radiotherapy. Mol. Ther. 33, 6033–6040 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zuniga, L. M. et al. Diarrheal dilemma: a case of post-CAR-T T-cell lymphoma presenting as refractory diarrhea. Am. J. Gastroenterol. 120, S1081–S1081 (2025).

Article  Google Scholar 

Rolak, S., Patel, C., Cheng, J., Eller, V. & Umar, S. Persistent diarrhea following CAR-T therapy for multiple myeloma: a case of immune effector cell-associated enterocolitis.Am. J. Gastroenterol. 120, S1305–S1305 (2025).

Google Scholar 

Aleman, A. et al. Targeted therapy of CAR+ T-cell lymphoma after anti-BCMA CAR T-cell therapy. N. Engl. J. Med. 393, 823–825 (2025).

Article  PubMed  PubMed Central  Google Scholar 

Braun, T. et al. Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. Nat. Med. 31, 1145–1153 (2025).

Article  CAS  PubMed  Google Scholar 

Harrison, S. J. et al. CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma. N. Engl. J. Med. 392, 677–685 (2025).

Article  CAS  PubMed  Google Scholar 

Micklethwaite, K. P. et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood 138, 1391–1405 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kobbe, G. et al. Aggressive lymphoma after CD19 CAR T-cell therapy. N. Engl. J. Med. 391, 1217–1226 (2024).

Article  CAS  PubMed  Google Scholar 

Hamilton, M. P. et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 390, 2047–2060 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984–989 (2024).

Article  CAS  PubMed  Google Scholar 

Godfrey, J., Querfeld, C. & Song, J. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 391, 869–870 (2024).

Article  PubMed  Google Scholar 

Li, P. et al. C-CAR039, a novel anti-CD20/CD19 bi-specific CAR T-cell therapy shows deep and durable clinical benefits in patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) in long term follow up. Blood 142, 1025–1025 (2023).

Article  Google Scholar 

Palomba, M. L. et al. Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. Lancet 407, 963–975 (2026).

Article  CAS  PubMed  Google Scholar 

Alaggio, R. et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36, 1720–1748 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Campo, E. et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 140, 1229–1253 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Leval, L., Gaulard, P. & Dogan, A. A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas. Blood 144, 1855–1872 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Savage, K. J. & De Leval, L. Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization. Haematologica 108, 3204–3210 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Dulery, R. et al. T cell malignancies after CAR T cell therapy in the DESCAR-T registry. Nat. Med. 31, 1130–1133 (2025).

Article  CAS  PubMed  Google Scholar 

Elsallab, M. et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood 143, 2099–2105 (2024).

Article  CAS  PubMed  Google Scholar 

Jadlowsky, J. K. et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat. Med. 31, 1134–1144 (2025).

Article  CAS  PubMed  Google Scholar 

Steffin, D. H. M. et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood 140, 16–24 (2022).

Article  CAS  PubMed  PubMed Central